{
    "clinical_study": {
        "@rank": "131285", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A: Placebo (Matching with BMS-986036 - Daily)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily  for 12 weeks"
            }, 
            {
                "arm_group_label": "Arm 2: Treatment B: BMS-986036 (1 mg Daily)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-986036 1 mg subcutaneous injection once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Treatment C: BMS-986036 (5 mg Daily)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-986036 5 mg subcutaneous injection once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Treatment D: BMS-986036 (20 mg Daily)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-986036 20 mg subcutaneous injection once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Treatment E: BMS-986036 (20 mg Weekly)", 
                "arm_group_type": "Experimental", 
                "description": "BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks\nFollowed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the potential of BMS-986036 for treatment obese\n      adults with type-2 diabetes."
        }, 
        "brief_title": "A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Diagnosed with type-2 diabetes mellitus with HbA1c >7.0% to less than 10.0%\n\n          -  Body mass index 30.0 to 40.0\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Inability to self-administer subcutaneous injections\n\n          -  Inability to be venipunctured\n\n          -  Evidence of organ dysfunction beyond what is consistent with the target population\n\n          -  History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21)\n             related compounds"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097277", 
            "org_study_id": "MB130-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 2: Treatment B: BMS-986036 (1 mg Daily)", 
                    "Treatment C: BMS-986036 (5 mg Daily)", 
                    "Treatment D: BMS-986036 (20 mg Daily)", 
                    "Treatment E: BMS-986036 (20 mg Weekly)"
                ], 
                "intervention_name": "BMS-986036", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Treatment A: Placebo (Matching with BMS-986036 - Daily)", 
                    "Treatment E: BMS-986036 (20 mg Weekly)"
                ], 
                "intervention_name": "Placebo (Matching with BMS-986036)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Kevin D Roberts, Site 0010", 
                    "phone": "501-907-9170"
                }, 
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72205"
                    }, 
                    "name": "Arkansas Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Amina Haggag, Site 0006", 
                    "phone": "714-774-7777", 
                    "phone_ext": "Ext201"
                }, 
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Anaheim Clinical Trials Llc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Juan Frias, Site 0013", 
                    "phone": "213-413-2500"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90057"
                    }, 
                    "name": "National Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robert S Lipetz, Site 0009", 
                    "phone": "619-660-9068"
                }, 
                "facility": {
                    "address": {
                        "city": "Spring Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91978"
                    }, 
                    "name": "Encompass Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lorena Lewy-Alterbaum, Site 0012", 
                    "phone": "754-263-2001"
                }, 
                "facility": {
                    "address": {
                        "city": "Cooper City", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33024"
                    }, 
                    "name": "All Medical Research, Llc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "James L Borders, Site 0011", 
                    "phone": "859-264-8999"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40509"
                    }, 
                    "name": "Central Kentucky Research Associates, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Fitzgibbons, Site 0015", 
                    "phone": "402-614-5083"
                }, 
                "facility": {
                    "address": {
                        "city": "Elkhorn", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68022"
                    }, 
                    "name": "Clinical Research Advantage, Inc./Skyline Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jane Rohlf, Site 0008", 
                    "phone": "609-392-6666"
                }, 
                "facility": {
                    "address": {
                        "city": "Trenton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08611"
                    }, 
                    "name": "Premier Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Karlton Pettis, Site 0014", 
                    "phone": "704-377-6906"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "Metrolina Internal Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Matthew Wenker, Site 0007", 
                    "phone": "513-381-4100"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "Sterling Research Grp, Ltd."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0003"
                }, 
                "facility": {
                    "address": {
                        "city": "Brampton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L6T 0G1"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0016"
                }, 
                "facility": {
                    "address": {
                        "city": "Drummondville", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J2B 7T1"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2R 1V6"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Victoriaville", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G6P 6P6"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G3K 2P8"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in glycosylated hemoglobin A1c (HbA1c) from baseline to Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1)  and Week 12"
            }, 
            {
                "measure": "Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 161 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Average concentration (Cavg) of BMS-986036", 
                "safety_issue": "No", 
                "time_frame": "13 time points up to 126 days"
            }, 
            {
                "measure": "Trough observed concentration (Cmin) of BMS-986036", 
                "safety_issue": "No", 
                "time_frame": "13 time points up to 126 days"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) of BMS-986036", 
                "safety_issue": "No", 
                "time_frame": "13 time points up to 126 days"
            }, 
            {
                "measure": "Area under the concentration-time curve (AUC) at steady state of BMS-986036", 
                "safety_issue": "No", 
                "time_frame": "13 time points up to 126 days"
            }, 
            {
                "measure": "Change or percent change in Body weight, Waist circumference and Body mass index (BMI) from baseline to Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and Week 12"
            }, 
            {
                "description": "Insulin sensitivity index include Homeostatic model assessment of Insulin resistance (HOMA-IR), Quantitative Insulin sensitivity check index (QUICKI) and Matsuda Index", 
                "measure": "Change or percent change in Insulin sensitivity indexes, calculated from Glucose and Insulin in oral glucose tolerance test (OGTT), from baseline to Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and Week 12"
            }, 
            {
                "measure": "Change or percent change in OGTT area under the curve from 0 to 120 minutes for postprandial glucose and Insulin response to an OGTT from baseline to Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and Week 12"
            }, 
            {
                "measure": "Change or percent change in fasting Plasma glucose, Serum Insulin and Serum C-peptide from baseline to Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and Week 12"
            }, 
            {
                "description": "Subjects will be monitored for antibodies to study medication and to FGF-21 with an anti-drug antibody assay and an anti-FGF21 assay. Titers will be reported for samples testing positive in either assay. In addition, subjects testing positive in either assay will be assessed for neutralizing antibodies with a functional cell based neutralizing antibody assay", 
                "measure": "Immunogenicity measures", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 161 days"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}